Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.07
LH's Cash to Debt is ranked lower than
94% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. LH: 0.07 )
Ranked among companies with meaningful Cash to Debt only.
LH' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.11 Max: 0.29
Current: 0.07
0.03
0.29
Equity to Asset 0.39
LH's Equity to Asset is ranked lower than
74% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. LH: 0.39 )
Ranked among companies with meaningful Equity to Asset only.
LH' s Equity to Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.41 Max: 0.63
Current: 0.39
0.35
0.63
Interest Coverage 6.01
LH's Interest Coverage is ranked lower than
78% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.16 vs. LH: 6.01 )
Ranked among companies with meaningful Interest Coverage only.
LH' s Interest Coverage Range Over the Past 10 Years
Min: 3.65  Med: 10.84 Max: 14.88
Current: 6.01
3.65
14.88
F-Score: 4
Z-Score: 2.51
M-Score: -2.50
WACC vs ROIC
8.39%
7.90%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 13.65
LH's Operating margin (%) is ranked higher than
79% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. LH: 13.65 )
Ranked among companies with meaningful Operating margin (%) only.
LH' s Operating margin (%) Range Over the Past 10 Years
Min: 11.55  Med: 17.58 Max: 19.94
Current: 13.65
11.55
19.94
Net-margin (%) 7.49
LH's Net-margin (%) is ranked higher than
74% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.64 vs. LH: 7.49 )
Ranked among companies with meaningful Net-margin (%) only.
LH' s Net-margin (%) Range Over the Past 10 Years
Min: 5.03  Med: 10.08 Max: 11.72
Current: 7.49
5.03
11.72
ROE (%) 13.65
LH's ROE (%) is ranked higher than
78% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.95 vs. LH: 13.65 )
Ranked among companies with meaningful ROE (%) only.
LH' s ROE (%) Range Over the Past 10 Years
Min: 11.25  Med: 22.19 Max: 28.64
Current: 13.65
11.25
28.64
ROA (%) 5.05
LH's ROA (%) is ranked higher than
70% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.53 vs. LH: 5.05 )
Ranked among companies with meaningful ROA (%) only.
LH' s ROA (%) Range Over the Past 10 Years
Min: 4.06  Med: 8.75 Max: 11.43
Current: 5.05
4.06
11.43
ROC (Joel Greenblatt) (%) 52.42
LH's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.23 vs. LH: 52.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LH' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 52.42  Med: 104.98 Max: 138.05
Current: 52.42
52.42
138.05
Revenue Growth (3Y)(%) 13.50
LH's Revenue Growth (3Y)(%) is ranked higher than
81% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. LH: 13.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LH' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -21.4  Med: 10.5 Max: 19.9
Current: 13.5
-21.4
19.9
EBITDA Growth (3Y)(%) 8.90
LH's EBITDA Growth (3Y)(%) is ranked higher than
65% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. LH: 8.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
LH' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.3  Med: 8.35 Max: 17.6
Current: 8.9
-8.3
17.6
EPS Growth (3Y)(%) 3.90
LH's EPS Growth (3Y)(%) is ranked higher than
58% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. LH: 3.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
LH' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.2  Med: 15.35 Max: 82.8
Current: 3.9
-10.2
82.8
GuruFocus has detected 4 Warning Signs with Laboratory Corp of America Holdings $LH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LH's 10-Y Financials

Financials (Next Earnings Date: 2017-04-25)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

LH Guru Trades in Q1 2016

Joel Greenblatt 262,389 sh (New)
David Dreman 3,169 sh (+552.06%)
Mario Gabelli 20,400 sh (+264.29%)
Jim Simons 281,805 sh (+139.82%)
Ray Dalio 28,200 sh (+56.44%)
Paul Tudor Jones 262,144 sh (+49.80%)
Wallace Weitz 777,949 sh (+11.13%)
Scott Black 20,375 sh (+4.43%)
Pioneer Investments 26,829 sh (unchged)
First Pacific Advisors 50,400 sh (unchged)
Richard Pzena Sold Out
Jana Partners Sold Out
John Paulson Sold Out
Larry Robbins 5,456,575 sh (-3.54%)
Chris Davis 1,701,662 sh (-4.34%)
Jeff Auxier 3,180 sh (-4.50%)
John Rogers 1,587,342 sh (-5.25%)
Keeley Asset Management Corp 57,675 sh (-27.13%)
Jeremy Grantham 3,900 sh (-73.47%)
Andreas Halvorsen 673,048 sh (-79.02%)
» More
Q2 2016

LH Guru Trades in Q2 2016

Wallace Weitz 805,459 sh (+3.54%)
Jeff Auxier 3,180 sh (unchged)
Pioneer Investments 26,829 sh (unchged)
Larry Robbins 5,456,575 sh (unchged)
Chris Davis Sold Out
Jeremy Grantham Sold Out
Andreas Halvorsen Sold Out
Scott Black 19,523 sh (-4.18%)
John Rogers 1,514,925 sh (-4.56%)
Paul Tudor Jones 236,880 sh (-9.64%)
Mario Gabelli 17,400 sh (-14.71%)
David Dreman 2,683 sh (-15.34%)
Keeley Asset Management Corp 47,176 sh (-18.20%)
Jim Simons 202,905 sh (-28.00%)
Ray Dalio 19,513 sh (-30.80%)
Joel Greenblatt 170,923 sh (-34.86%)
First Pacific Advisors 20,400 sh (-59.52%)
» More
Q3 2016

LH Guru Trades in Q3 2016

John Hussman 25,000 sh (New)
Richard Pzena 2,185 sh (New)
First Eagle Investment 226,794 sh (New)
Ray Dalio 30,844 sh (+58.07%)
David Dreman 2,683 sh (unchged)
First Pacific Advisors 20,400 sh (unchged)
Pioneer Investments 26,829 sh (unchged)
Wallace Weitz 766,205 sh (-4.87%)
John Rogers 1,438,798 sh (-5.03%)
Jeff Auxier 2,980 sh (-6.29%)
Keeley Asset Management Corp 43,106 sh (-8.63%)
Scott Black 17,477 sh (-10.48%)
Larry Robbins 4,212,026 sh (-22.81%)
Jim Simons 146,205 sh (-27.94%)
Joel Greenblatt 82,365 sh (-51.81%)
Mario Gabelli 5,400 sh (-68.97%)
Paul Tudor Jones 3,400 sh (-98.56%)
» More
Q4 2016

LH Guru Trades in Q4 2016

Richard Snow 16,700 sh (New)
Charles Brandes 54,221 sh (New)
Joel Greenblatt 149,653 sh (+81.69%)
First Eagle Investment 268,515 sh (+18.40%)
Richard Pzena 2,327 sh (+6.50%)
John Rogers 1,470,340 sh (+2.19%)
Wallace Weitz 778,751 sh (+1.64%)
Mario Gabelli 5,400 sh (unchged)
First Pacific Advisors 20,400 sh (unchged)
David Dreman 2,683 sh (unchged)
John Hussman Sold Out
Larry Robbins 4,188,260 sh (-0.56%)
Scott Black 17,076 sh (-2.29%)
Keeley Asset Management Corp 40,406 sh (-6.26%)
Pioneer Investments 21,636 sh (-19.36%)
Paul Tudor Jones 1,800 sh (-47.06%)
Jim Simons 67,800 sh (-53.63%)
Ray Dalio 10,400 sh (-66.28%)
» More
» Details

Insider Trades

Latest Guru Trades with LH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NYSE:DGX, NAS:IDXX, NYSE:A, OTCPK:SSMXY, NYSE:Q, NAS:DXCM, NAS:QGEN, OTCPK:BMXMF, NYSE:PKI, NYSE:BIO.B, NAS:ICLR, NAS:BRKR, NYSE:CRL, NAS:PRAH, NAS:VWR, NYSE:ALR, NAS:PRXL, OTCPK:CZMWY, NAS:INCR, NAS:NEOG » details
Traded in other countries:LAB.Germany,
Laboratory Corp of America Hldgs offers testing services used by the medical profession in core testing, patient diagnosis and in the monitoring and treatment of disease.

Laboratory Corp of America Holdings was founded in 1971, is an independent clinical laboratory company in the United States. The Company along with its subsidiaries provides clinical laboratory services and end-to-end drug development support. Its segments include LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). LCD is an independent clinical laboratory business offers a focused menu of routine and frequently ordered tests with the ability to perform quickly and report the results to the physician. CDD offers drug development services, provides a range of drug development solutions, to companies in the pharmaceutical and biotechnology industries. LCD offers its diagnostic services through a sales force focused on serving the specific needs of customers in different market segments. These market segments generally include Primary Care, Obstetrics-Gynecology, Specialty Medicine (e.g., Infectious Disease, Endocrinology, Gastroenterology and Rheumatology), Oncology and Hospitals. CDD's sales activities are conducted by sales personnel in North America, Europe, South America and the Asia Pacific region. The sales force provides client coverage across the biopharmaceutical industry for services including optimization, preclinical safety assessment, analytical services, clinical solutions, central laboratories and market access solutions. LCD competes on the basis of quality of testing, breadth of menu, price, innovation of services, convenience and access points throughout the nation. The Company is subject to licensing and regulation under federal, state and local laws and regulations relating to the protection of the environment and human health and safety and laws and regulations relating to the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials.

Guru Investment Theses on Laboratory Corp of America Holdings

Wally Weitz Comments on Laboratory Corp of America - Jul 20, 2016

Laboratory Corp. of America (NYSE:LH) is a healthcare diagnostics company providing comprehensive clinical laboratory services to medical professionals and end-to-end drug development support to pharmaceutical manufacturers. LabCorp reported stronger than expected organic growth during the first quarter in both its diagnostics and drug development segments and raised its financial forecast for the full year. Covance, its drug development segment, has demonstrated improving operating momentum the past three quarters, with strength across each of its primary end markets (pre-clinical, central lab, late stage). Finally, the Center for Medicare and Medicaid Services’ (CMS’) highly anticipated Final Rule on changes to the Medicare Clinical Lab Fee Schedule in mid-June included two positives for the lab industry – a delay in implementation until 2018 and the inclusion of higher cost outpatient hospital labs, which is a piece that will determine future reimbursement levels. While final details won’t be known for some time, we anticipate these reimbursement changes will have a very modest impact on LabCorp’s future earnings power.



From Weitz Partners Fund's second quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Weitz Funds Comments on Laboratory Corp. of America Holdings - Apr 25, 2016

Laboratory Corp. of America Holdings (NYSE:LH) is the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to -end drug development support. The company’s strong competitive position, durable excess cash flow and exemplary management have been mainstays of the Laboratory Corp. investment thesis over many years. Various Weitz managed portfolios have been investors in the company over the past 10+ years. We initiated the position, as both the diagnostic lab and drug development market continued to experience healthy demand. A little over one year in, LabCorp’s $6 billion acquisition of Covance appears to be bearing early fruit in the form of new customer wins and central lab market share gains. With revenue and cost synergies on track, financial leverage returning to target levels and stable reimbursement, we believe this stock can compound wealth for years to come.



From Weitz Funds' Research Fund commentary 1st quarter.



Check out Wallace Weitz latest stock trades

Weitz Funds Comments on Laboratory Corporation of America Holdings - Feb 01, 2016

Laboratory Corporation of America Holdings (NYSE:LH) offers testing services used by medical professionals in core testing, patient diagnosis and the monitoring and treatment of disease. LabCorp shares rose during the fourth quarter, rebounding after a poor month in September. The company’s most recent financial results showed continued strength in the legacy Diagnostics segment with +5% organic sales growth versus the prior year and a healthy increase in profitability. Results in the still relatively new Covance Drug Development business improved, consistent with management’s expectations earlier in the year. Following a 3-year period of relatively stagnant growth, LabCorp appears poised for a return to healthy, double-digit per share earnings growth over the next several years as the company leverages the commercial strength of its combined operations.



From Weitz Funds' Balanced Fund fourth quarter 2015 commentary.



Check out Wallace Weitz latest stock trades

Top Ranked Articles about Laboratory Corp of America Holdings

Wally Weitz Comments on Laboratory Corp of America Guru stock highlight
Laboratory Corp. of America (NYSE:LH) is a healthcare diagnostics company providing comprehensive clinical laboratory services to medical professionals and end-to-end drug development support to pharmaceutical manufacturers. LabCorp reported stronger than expected organic growth during the first quarter in both its diagnostics and drug development segments and raised its financial forecast for the full year. Covance, its drug development segment, has demonstrated improving operating momentum the past three quarters, with strength across each of its primary end markets (pre-clinical, central lab, late stage). Finally, the Center for Medicare and Medicaid Services’ (CMS’) highly anticipated Final Rule on changes to the Medicare Clinical Lab Fee Schedule in mid-June included two positives for the lab industry – a delay in implementation until 2018 and the inclusion of higher cost outpatient hospital labs, which is a piece that will determine future reimbursement levels. While final details won’t be known for some time, we anticipate these reimbursement changes will have a very modest impact on LabCorp’s future earnings power.
From Read more...
Weitz Funds Comments on Laboratory Corp. of America Holdings Guru stock highlight
Laboratory Corp. of America Holdings (NYSE:LH) is the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to -end drug development support. The company’s strong competitive position, durable excess cash flow and exemplary management have been mainstays of the Laboratory Corp. investment thesis over many years. Various Weitz managed portfolios have been investors in the company over the past 10+ years. We initiated the position, as both the diagnostic lab and drug development market continued to experience healthy demand. A little over one year in, LabCorp’s $6 billion acquisition of Covance appears to be bearing early fruit in the form of new customer wins and central lab market share gains. With revenue and cost synergies on track, financial leverage returning to target levels and stable reimbursement, we believe this stock can compound wealth for years to come. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 20.10
LH's P/E(ttm) is ranked higher than
72% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.58 vs. LH: 20.10 )
Ranked among companies with meaningful P/E(ttm) only.
LH' s P/E(ttm) Range Over the Past 10 Years
Min: 13  Med: 17.25 Max: 29.35
Current: 20.1
13
29.35
Forward P/E 14.56
LH's Forward P/E is ranked higher than
98% of the 45 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.46 vs. LH: 14.56 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 20.10
LH's PE(NRI) is ranked higher than
70% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.65 vs. LH: 20.10 )
Ranked among companies with meaningful PE(NRI) only.
LH' s PE(NRI) Range Over the Past 10 Years
Min: 13  Med: 17.25 Max: 29.35
Current: 20.1
13
29.35
Price/Owner Earnings (ttm) 17.16
LH's Price/Owner Earnings (ttm) is ranked higher than
80% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.11 vs. LH: 17.16 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
LH' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.35  Med: 14.37 Max: 42.34
Current: 17.16
9.35
42.34
P/B 2.60
LH's P/B is ranked higher than
67% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. LH: 2.60 )
Ranked among companies with meaningful P/B only.
LH' s P/B Range Over the Past 10 Years
Min: 2.11  Med: 3.46 Max: 5.19
Current: 2.6
2.11
5.19
P/S 1.50
LH's P/S is ranked higher than
79% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.42 vs. LH: 1.50 )
Ranked among companies with meaningful P/S only.
LH' s P/S Range Over the Past 10 Years
Min: 1.19  Med: 1.64 Max: 3
Current: 1.5
1.19
3
PFCF 16.21
LH's PFCF is ranked higher than
77% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.89 vs. LH: 16.21 )
Ranked among companies with meaningful PFCF only.
LH' s PFCF Range Over the Past 10 Years
Min: 9.24  Med: 14.74 Max: 32.44
Current: 16.21
9.24
32.44
POCF 12.37
LH's POCF is ranked higher than
76% of the 87 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.57 vs. LH: 12.37 )
Ranked among companies with meaningful POCF only.
LH' s POCF Range Over the Past 10 Years
Min: 7.53  Med: 11.37 Max: 21.26
Current: 12.37
7.53
21.26
EV-to-EBIT 14.86
LH's EV-to-EBIT is ranked higher than
77% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.83 vs. LH: 14.86 )
Ranked among companies with meaningful EV-to-EBIT only.
LH' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.7  Med: 11.7 Max: 21.4
Current: 14.86
8.7
21.4
EV-to-EBITDA 10.80
LH's EV-to-EBITDA is ranked higher than
75% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.07 vs. LH: 10.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
LH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.2  Med: 9.6 Max: 16.1
Current: 10.8
7.2
16.1
PEG 2.89
LH's PEG is ranked higher than
63% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. LH: 2.89 )
Ranked among companies with meaningful PEG only.
LH' s PEG Range Over the Past 10 Years
Min: 0.86  Med: 1.56 Max: 6.18
Current: 2.89
0.86
6.18
Shiller P/E 24.76
LH's Shiller P/E is ranked higher than
79% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 40.88 vs. LH: 24.76 )
Ranked among companies with meaningful Shiller P/E only.
LH' s Shiller P/E Range Over the Past 10 Years
Min: 18.84  Med: 23.47 Max: 56.37
Current: 24.76
18.84
56.37
Current Ratio 1.36
LH's Current Ratio is ranked lower than
80% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. LH: 1.36 )
Ranked among companies with meaningful Current Ratio only.
LH' s Current Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.61 Max: 3.1
Current: 1.36
0.79
3.1
Quick Ratio 1.24
LH's Quick Ratio is ranked lower than
76% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. LH: 1.24 )
Ranked among companies with meaningful Quick Ratio only.
LH' s Quick Ratio Range Over the Past 10 Years
Min: 0.72  Med: 1.5 Max: 2.91
Current: 1.24
0.72
2.91
Days Inventory 10.99
LH's Days Inventory is ranked higher than
89% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.66 vs. LH: 10.99 )
Ranked among companies with meaningful Days Inventory only.
LH' s Days Inventory Range Over the Past 10 Years
Min: 10.44  Med: 12.14 Max: 13.23
Current: 10.99
10.44
13.23
Days Sales Outstanding 50.30
LH's Days Sales Outstanding is ranked higher than
69% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.91 vs. LH: 50.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
LH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.64  Med: 49.42 Max: 55.91
Current: 50.3
44.64
55.91
Days Payable 28.72
LH's Days Payable is ranked lower than
74% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.58 vs. LH: 28.72 )
Ranked among companies with meaningful Days Payable only.
LH' s Days Payable Range Over the Past 10 Years
Min: 20.61  Med: 27.89 Max: 32.38
Current: 28.72
20.61
32.38

Buy Back

vs
industry
vs
history
Yield on cost (5-Year) 0.60
LH's Yield on cost (5-Year) is ranked lower than
82% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.65 vs. LH: 0.60 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
LH' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 0.6
3-Year Average Share Buyback Ratio -6.30
LH's 3-Year Average Share Buyback Ratio is ranked lower than
52% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. LH: -6.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -42.1  Med: 3.3 Max: 6.6
Current: -6.3
-42.1
6.6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.06
LH's Price/Projected FCF is ranked higher than
81% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.11 vs. LH: 1.06 )
Ranked among companies with meaningful Price/Projected FCF only.
LH' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.74  Med: 1.01 Max: 6.11
Current: 1.06
0.74
6.11
Price/DCF (Earnings Based) 1.82
LH's Price/DCF (Earnings Based) is ranked lower than
56% of the 16 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.71 vs. LH: 1.82 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.92
LH's Price/Median PS Value is ranked higher than
65% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. LH: 0.92 )
Ranked among companies with meaningful Price/Median PS Value only.
LH' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.07  Med: 0.96 Max: 1.68
Current: 0.92
0.07
1.68
Price/Peter Lynch Fair Value 3.11
LH's Price/Peter Lynch Fair Value is ranked lower than
67% of the 21 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.42 vs. LH: 3.11 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
LH' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.96  Med: 1.6 Max: 3.83
Current: 3.11
0.96
3.83
Earnings Yield (Greenblatt) (%) 6.73
LH's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 226 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. LH: 6.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LH' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.7  Med: 8.5 Max: 11.4
Current: 6.73
4.7
11.4
Forward Rate of Return (Yacktman) (%) 11.59
LH's Forward Rate of Return (Yacktman) (%) is ranked higher than
62% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. LH: 11.59 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
LH' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 9.9  Med: 17.9 Max: 22.6
Current: 11.59
9.9
22.6

More Statistics

Revenue (TTM) (Mil) $9,642
EPS (TTM) $ 6.92
Beta1.14
Short Percentage of Float2.28%
52-Week Range $107.59 - 141.32
Shares Outstanding (Mil)103.00

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 9,914 10,305 10,723
EPS ($) 9.55 10.29 11.02
EPS w/o NRI ($) 9.55 10.29 11.02
EPS Growth Rate
(3Y to 5Y Estimate)
10.68%
Dividends Per Share ($)
» More Articles for LH

Headlines

Articles On GuruFocus.com
6 Stocks With High Business Predictability Jan 31 2017 
Chris Davis Buys Activision Blizzard, Sells Amazon.com Aug 22 2016 
Healthcare Growth Stocks in the S&P 500: Part 2 Aug 12 2016 
Healthcare Growth Stocks in the S&P 500: Part 2 Aug 12 2016 
Wally Weitz Comments on Laboratory Corp of America Jul 20 2016 
Wally Weitz's Partners Value Fund 2Q 2016 Quarterly Commentary Jul 20 2016 
Wallace Weitz's Best-Performing Stocks Jul 07 2016 
5 Companies Achieve 52-Week Highs May 24 2016 
Weitz Funds Comments on Laboratory Corp. of America Holdings Apr 25 2016 
7 High Quality Guru Stocks Apr 11 2016 

More From Other Websites
Laboratory Corp. of America Holdings :LH-US: Earnings Analysis: 2016 By the Numbers : February 21,... Feb 21 2017
Laboratory Corp. of America Holdings :LH-US: Earnings Analysis: Q4, 2016 By the Numbers : February... Feb 17 2017
Edited Transcript of LH earnings conference call or presentation 16-Feb-17 2:00pm GMT Feb 16 2017
Amid M&A Buzz, LabCorp CEO Says Deal Pipeline 'Very Healthy' Feb 16 2017
Laboratory Corporation 4Q Earnings Beats Street Feb 16 2017
LabCorp (LH) Q4 Earnings and Revenues Beat, Offers View Feb 16 2017
LabCorp to acquire Washington company, per report Feb 16 2017
Laboratory Corporation of America Holdings Earnings Call scheduled for 9:00 am ET today Feb 16 2017
LabCorp (LH) Beats on Q4 Earnings & Revenue Estimates Feb 16 2017
LabCorp tops Street 4Q forecasts Feb 16 2017
LabCorp tops Street 4Q forecasts Feb 16 2017
Q4 2016 Laboratory Corporation of America Holdings Earnings Release - Before Market Open Feb 16 2017
LABORATORY CORP OF AMERICA HOLDINGS Files SEC form 8-K, Regulation FD Disclosure Feb 16 2017
Laboratory Corporation of America® Holdings Announces Record 2016 Fourth Quarter and Full Year... Feb 16 2017
MedTech Stocks' Q4 Earnings on Feb 16: LH, WST and MDRX Feb 15 2017
LabCorp (LH) Q4 Earnings: What's in the Cards for the Stock? Feb 14 2017
Laboratory Corp. of America Holdings breached its 50 day moving average in a Bullish Manner : LH-US... Feb 08 2017
Company News for February 07, 2017 Feb 07 2017
Labcorp: Not That Deal, Please Feb 07 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)